N. Agarwal

EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees

Alan Horwich, Marek Babjuk, Joaquim Bellmunt et al. · Annals of Oncology · 2019 · 182 citations · Full text

Medicine, Oncology, Urology +17

Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials

D.Y.C. Heng, Toni K. Choueiri, Brian I. Rini et al. · Annals of Oncology · 2013 · 147 citations · Full text

Medicine, Nephrology, Oncology +13

Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel

Heather H. Cheng, Roman Gulati, Arun Azad et al. · Prostate Cancer and Prostatic Diseases · 2015 · 83 citations · Full text

Medicine, Oncology, Pharmacology +15

Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)

Aristotelis Bamias, Kimon Tzannis, L.C. Harshman et al. · Annals of Oncology · 2017 · 71 citations · Full text

Medicine, Oncology, Urology +9

First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC

Jenny J. Ko, Toni K. Choueiri, Brian I. Rini et al. · British Journal of Cancer · 2014 · 70 citations · Full text

Medicine, Biostatistics, Oncology +13